Tag: Algernon Pharmaceuticals - Psychedelic Alpha

Our Oregon Local Jurisdiction Tracker is available now.

Read more about the article Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

Post published:August 3, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Post published:July 30, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Post published:July 19, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Post published:July 12, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Post published:July 7, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Post published:July 7, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Post published:June 29, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Post published:June 22, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Post published:January 24, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Post published:January 19, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.